Interviews with and commentary from experts and innovators in hematology.

ASH Annual Meeting

Is Rivaroxaban Safe as Long-Term Prevention for Deep-Vein Thrombosis?

Multiple Advances in Multiple Myeloma

What Was Hot at ASH 2015?

Rivaroxaban in Cancer-Associated VTE: Results from CALLISTO

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL

The Balancing Act of Caring for Older Patients with Hemophilia

Ibrutinib Beats Temsirolimus in Relapsed/Refractory MCL

Improving Quality of VTE Care

The PROs of Patient-Reported Outcomes

Induction Chemotherapy for AML: Understanding the Patient Experience

Late-Breaking Abstract: First-in-Man Trial of CAR T Cells in Myeloma

Ixazomib Extends PFS in the TOURMALINE-MM1 Trial

Evolving Issues in Anticoagulation

Predicting Prognosis in Myelodysplastic Syndromes

New Approaches in CLL and Prolymphocytic Leukemia

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

Optimizing Therapy in Sickle Cell Disease

Controversy over Quality

Eligibility Criteria Not Associated with Adverse Events in RCTs

Newly Approved Drugs: How Should We Use Them in the Clinic?

Guiding Hematologic Care with Genetic Testing

ASH Meeting on Hematologic Malignancies

Brad Schenkel, MSc: Predicting Hospitalizations, ER Visits Among CLL Patients

Jaleh Fallah, MD: Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL Patients?

Asher Alban Chanan-Khan, MD: Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

Ksenia Romanova, MD: Age, Sex, Timing of Treatment Predict Avascular Necroses in Children with ALL

Collaborative Care Delivery Reduces Travel Burden for AML Patients

Highlights of the 2015 ASH Meeting on Hematologic Malignancies

HIV-Associated Lymphoma: Treatment Patterns and Survival in the Antiretroviral Era

The Future of Clinical and Translational Research in Hematologic Malignancies

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma Patients

Non-ASH Meetings

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Study Finds Thrombosis Risk Changes Throughout Myeloma Disease Course

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma Patients

TOURMALINE-MM3 and 4: Ixazomib as Maintenance Therapy in Myeloma Patients

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Ruxolitinib in CMML: Study Shows Promising Results

Options for Treating the High-Risk APL Patient

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

back to top